Wnt10b-overexpressing umbilical cord mesenchymal stem cells promote critical size rat calvarial defect healing by enhanced osteogenesis and VEGF-mediated angiogenesis
Liu Y., Fang J., Zhang Q., Zhang X., Cao Y., Chen W.
Animal Study, published in J Orthop Translat (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Orthop Translat (2020)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 32477867
- PMCID
- PMC7248289
- DOI
- 10.1016/j.jot.2020.02.009
- Citations
- 33
Abstract (original English)
Background/objectives Accelerating the process of bone regeneration is of great interest for surgeons and basic scientists alike. Recently, umbilical cord mesenchymal stem cells (UCMSCs) are considered clinically applicable for tissue regeneration due to their noninvasive harvesting and better viability. Nonetheless, the bone regenerative ability of human UCMSCs (HUCMSCs) is largely unknown. This study aimed to investigate whether Wnt10b-overexpressing HUCMSCs have enhanced bone regeneration ability in a rat model. Method A rat calvarial defect was performed on 8-week old male Sprague Dawley rats. Commercially purchased HUCMSCs Emp in hydrogel, HUCMSCs Wnt10b in hydrogel and HUCMSCs Wnt10b with IWR-1 were placed in the calvarial bone defect right after surgery on rats ( N = 8 rats for each group). Calvaria were harvested for micro-CT analysis and histology four weeks after surgery. CFU-F and multi-differentiation assay by oil red staining, alizarin red staining and RT-PCR (real-time polymerase chain reaction) were performed on HUCMSCs Emp and HUCMSCs Wnt10b in vitro . Conditioned media from HUCMSCs Emp and HUCMSCs Wnt10b were collected and used to treat human umbilical cord vein endothelial cells in Matrigel to access vessel formation capacity by tube formation assay. Results Alizarin red staining, oil red staining and RT-PCR results showed robust osteogenic differentiation but
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.